Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NHS England/NICE Consultation Could Spell Market Access Complications

Executive Summary

Companies with innovative and expensive drugs may face additional hurdles to get their products to the market in England, according to a consultation from NICE, England's health technology appraisal institute, and NHS England.

You may also be interested in...



UK Report Casts Doubt Over Use Of QALYs When Appraising Ultra Orphans

Office of Health Economics suggests additional criteria could include social preferences on treating patients with very rare diseases, impact beyond direct health benefits, or adjustments for low patient numbers.

BIA Says NHS Funding Changes Would Jeopardize Life Science Sector, As UK PM Announces ‘Hard’ Brexit

As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.

Brexit Issues Lead NICE To Delay Methods Review

England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”

Topics

Related Companies

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel